Deerfield Management Company L.P. Series C Lowers Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Deerfield Management Company L.P. Series C trimmed its holdings in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 92.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 534,737 shares of the company's stock after selling 6,180,764 shares during the period. Deerfield Management Company L.P. Series C owned approximately 0.76% of Ventyx Biosciences worth $1,171,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Bank of America Corp DE increased its position in shares of Ventyx Biosciences by 376.4% in the 4th quarter. Bank of America Corp DE now owns 4,273,442 shares of the company's stock valued at $9,359,000 after buying an additional 3,376,446 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Ventyx Biosciences by 88.6% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 871,527 shares of the company's stock valued at $1,909,000 after purchasing an additional 409,357 shares during the period. Renaissance Technologies LLC boosted its position in shares of Ventyx Biosciences by 99.1% during the fourth quarter. Renaissance Technologies LLC now owns 624,500 shares of the company's stock worth $1,368,000 after buying an additional 310,800 shares during the period. Boothbay Fund Management LLC grew its holdings in shares of Ventyx Biosciences by 472.2% during the fourth quarter. Boothbay Fund Management LLC now owns 314,891 shares of the company's stock worth $690,000 after buying an additional 259,863 shares in the last quarter. Finally, Monaco Asset Management SAM acquired a new stake in Ventyx Biosciences in the 4th quarter valued at approximately $526,000. 97.88% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "neutral" rating on shares of Ventyx Biosciences in a report on Tuesday, January 14th.

Ventyx Biosciences Stock Up 0.8%

Shares of VTYX stock traded up $0.01 during trading on Tuesday, reaching $1.22. 644,749 shares of the company's stock were exchanged, compared to its average volume of 1,286,179. The firm's fifty day moving average price is $1.21 and its 200-day moving average price is $1.78. The stock has a market capitalization of $86.82 million, a PE ratio of -0.52 and a beta of 0.73. Ventyx Biosciences, Inc. has a twelve month low of $0.78 and a twelve month high of $5.66.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.09. As a group, analysts anticipate that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.